Research · PMID 42081070

PubMed sourcedAbstract-based analysis

Reviewed by Neal Rouzier, MD, Preventive Medicine · Sep 2026

Once-weekly somapacitan vs. daily norditropin in GHD: a systematic review and meta-analysis of efficacy and safety in children and adults.

Endocrine · May 2026 · Sarah Azhar, Mohammad Daniyal, Roshni Riaz Memon, Hamza Sajid, Nad E Ali Yousfani, et al.

What this study found

Once-weekly somapacitan demonstrates comparable efficacy and safety to daily Norditropin while offering greater convenience that may improve treatment adherence. These findings support somapacitan as a promising therapeutic option for patients with GHD, although long-term real-world studies are needed to confirm susta…

systematic_review

How RAGMD uses this study

Clinical questions this paper informs

Synthesis lives on the evidence question — this page shows where the study sits in that analysis.

Core study

When is growth hormone replacement appropriate in adults?

Growth hormone replacement is evidence-supported for adults with confirmed GH deficiency from pituitary disease, improving body composition and quality of life. Use in healthy aging or performance enhancement lacks safety and efficacy evidence.

Open evidence analysis

Supporting literature

Does vitamin D supplementation reduce mortality or major disease?

Meta-analyses show vitamin D supplementation does not significantly reduce all-cause mortality in unselected populations. Targeted repletion may benefit those with documented deficiency.

Open evidence analysis

Supporting literature

Does magnesium supplementation improve metabolic health markers?

Trials in deficient or at-risk individuals show modest improvements in some glycemic and blood pressure markers, but routine supplementation for metabolic disease prevention is not strongly supported in general populations.

Open evidence analysis

Supporting literature

Does DHEA supplementation improve health outcomes in aging adults?

DHEA raises circulating androgens and estrogens modestly but lacks robust outcome trial evidence for cardiovascular, cognitive, or mortality benefit in healthy aging adults without documented deficiency.

Open evidence analysis